Author

Nicholas Blazanin

The University of Texas MD Anderson Cancer CenterORCID 0009-0000-4171-1624Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Organism:mouse· 2 Assay:proteomics· 2 Assay:DNA methylation· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Yonathan LissanuiD· 3 shared Philip L. LorenziiD· 2 shared Xiaobing Liang· 2 shared Alessandro CarugoiD· 1 shared Andrea VialeiD· 1 shared Angela K. DeemiD· 1 shared Ben VanderkrukiD· 1 shared Brad G. HoffmaniD· 1 shared

Activity by Year

2024-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Yonathan LissanuORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyJournal of Medicinal ChemistryPeer-reviewedApr 25, 2025

Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C Inhibitors.

Sasikumar Kotagiri, Yawen Wang, Yanyan Han…·Yonathan Lissanu

This paper discovers and characterizes potent SMARCA2 PROTACs that show anti-tumor activity and synergize with KRAS G12C inhibitors in SMARCA4 mutant lung cancer.

12 citations

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintOct 21, 2024

WRAD core perturbation impairs DNA replication fidelity promoting immunoediting in pancreatic cancer

Francesca Citron, I-Lin Ho, Chiara Balestrieri…·Giulio Francesco Draetta

This study shows that disrupting the WRAD core in pancreatic cancer leads to DNA replication errors, immune response activation, and improved response to immune checkpoint inhibitors.

2 citations

mousehuman

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 16, 2024

Therapeutic modulation of ROCK overcomes metabolic adaptation of cancer cells to OXPHOS inhibition and drives synergistic anti-tumor activity

Nicholas Blazanin, Xiaobing Liang, Iqbal Mahmud…·Yonathan Lissanu

This study identifies ROCK inhibition as a strategy to overcome metabolic adaptation in cancer cells to OXPHOS inhibition, showing synergistic anti-tumor effects.

5 citations

humanproteomics

𝕏 PostBluesky